Dietze Zara, Marin-Cuartas Mateo, Berkei Livia, De La Cuesta Manuela, Otto Wolfgang, Pfannmüller Bettina, Kiefer Philipp, Misfeld Martin, Dashkevich Alexey, Kang Jagdip, Leontyev Sergey, Borger Michael A, Noack Thilo, Vollroth Marcel
University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany.
Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
JTCVS Open. 2024 Sep 2;22:191-207. doi: 10.1016/j.xjon.2024.07.021. eCollection 2024 Dec.
This study compares early and long-term outcomes following mitral valve (MV) repair and replacement in patients with mitral regurgitation (MR) and reduced left ventricular ejection fraction (LVEF).
Patients with primary or secondary MR and LVEF <50% who underwent MV replacement or repair (with/without atrial septal defect closure and/or atrial fibrillation ablation) between 2005 and 2017 at our center were retrospectively analyzed using unadjusted and propensity score matching techniques (42 pairs).
A total of 356 patients with either primary (n = 162 [45.5%]) or secondary MR (n = 194 [54.5%]) and LVEF <50% underwent MV repair (n = 293 [82.3%]) or replacement (n = 63 [17.7%]) during the study period. In-hospital mortality was 0.3% (repair) and 1.6% (replacement) in the unmatched cohort ( = .32); there were no in-hospital deaths after matching. Estimated survival was 72.8% (repair) versus 50.1% (replacement) at 8 years in the unmatched ( < .001), and 64.3% (repair) versus 50.7% (replacement) in the matched groups ( = .028). Eight-year cumulative incidence of reoperation was 7.0% and 11.6% in unmatched ( = .28), and 9.9% and 12.7% in matched ( = .69) repair and replacement groups, respectively. Markedly reduced LVEF (<40%) was among the independent predictors of long-term mortality (hazard ratio, 1.7; 95% CI, 1.2-2.4; = .002). In secondary MR, MV repair showed an 8-year survival benefit over replacement (65.1% vs 44.6%; = .002), with no difference in reoperation rate (11.6% [repair] vs 17.0% [replacement]; = .11).
MV repair performed in primary or secondary MR and reduced LVEF provides superior long-term results compared with replacement. Severe LV dysfunction is a significant predictor of reduced survival following MV surgery.
本研究比较二尖瓣反流(MR)且左心室射血分数(LVEF)降低的患者行二尖瓣(MV)修复术和置换术后的早期及长期结果。
对2005年至2017年期间在本中心接受MV置换或修复(伴或不伴房间隔缺损闭合和/或心房颤动消融)的原发性或继发性MR且LVEF<50%的患者,采用未调整和倾向评分匹配技术(42对)进行回顾性分析。
在研究期间,共有356例原发性(n = 162 [45.5%])或继发性MR(n = 194 [54.5%])且LVEF<50%的患者接受了MV修复(n = 293 [82.3%])或置换(n = 63 [17.7%])。在未匹配队列中,住院死亡率在修复组为0.3%,置换组为1.6%(P = 0.32);匹配后无住院死亡病例。在未匹配组中,8年时的估计生存率修复组为72.8%,置换组为50.1%(P<0.001),匹配组中分别为64.3%和50.7%(P = 0.028)。未匹配组中修复组和置换组的8年再次手术累积发生率分别为7.0%和11.6%(P = 0.28),匹配组中分别为9.9%和12.7%(P = 0.69)。LVEF显著降低(<40%)是长期死亡率的独立预测因素之一(风险比,1.7;95%CI,1.2 - 2.4;P = 0.002)。在继发性MR中,MV修复术显示出比置换术更好的8年生存率(65.1%对44.6%;P = 0.002),再次手术率无差异(修复组为11.6%,置换组为17.0%;P = 0.11)。
在原发性或继发性MR且LVEF降低的患者中,MV修复术与置换术相比可提供更好的长期结果。严重的左心室功能障碍是MV手术后生存率降低的重要预测因素。